ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gilead Sciences will acquire CGI Pharmaceuticals, located in Branford, Conn., for up to $120 million in cash, most of which will be paid up front. The rest will come in recognition of clinical development milestones. CGI focuses on small-molecule protein kinase inhibitors. “The acquisition of CGI represents a unique opportunity to expand our research efforts in an interesting and promising area of drug discovery,” Gilead Chief Scientific Officer Norbert W. Bischofberger says. The companies expect to complete the deal in the third quarter, after which CGI will operate as a Gilead subsidiary.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter